CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
View original at finance.yahoo.comCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Feb…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The company made meaningful advances across multiple clinical and preclinical programs including encouraging data from zugo-cel in autoimmune disease and oncology
80% confidenceCompany expects to provide update on CTX611 in second half of 2026
80% confidenceApproximately 90% of patients in U.S. have reimbursed access to CASGEVY as of year-end 2025
80% confidenceCompany expects to initiate clinical trial for CTX340 in first half of 2026
80% confidenceCTX321 incorporates updated guide RNA demonstrating approximately two-fold greater potency in preclinical testing compared to CTX320
80% confidenceCTX611 program has potential to target multi-billion-dollar market opportunity including atrial fibrillation, venous thromboembolism, ischemic stroke, and other indications
80% confidencePatient initiations and first cell collections increased nearly three-fold in 2025 compared to 2024
80% confidenceCompany expects to initiate clinical trial for CTX460 in mid-2026
80% confidenceCompany expects to provide update on CTX310 in second half of 2026
80% confidenceCRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline
80% confidenceGlobal regulatory submissions for CASGEVY in children ages 5-11 expected to begin in first half of 2026
80% confidenceCompany expects to provide updates on zugo-cel in autoimmune disease and immuno-oncology in second half of 2026
80% confidence